Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd, Inc. IVVD.OQ reported a quarterly adjusted loss of 14 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of three analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -15 cents to -3 cents per share.
Revenue rose 21.2% to $14.29 million from a year ago; analysts expected $14.40 million.
Invivyd, Inc.'s reported EPS for the quarter was a loss of 14 cents.
The company reported a quarterly loss of $44.39 million.
Invivyd, Inc. shares had fallen by 16.1% this quarter and lost 70.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 6.7% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Invivyd, Inc. is $10.00, about 92.7% above its last closing price of $0.73
This summary was machine generated from LSEG data August 13 at 09:06 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.11 | -0.14 | Missed |
Mar. 31 2026 | -0.07 | -0.13 | Missed |
Dec. 31 2025 | -0.09 | -0.04 | Beat |
Sep. 30 2025 | -0.08 | -0.06 | Beat |
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview